Keywords: Deficit schizophrenia; Cytokine; CD28; CTLA-4; Gene; Polymorphism;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Thyroiditis; PD-1; CTLA-4; Ipilimumab; Nivolumab; Cytology;
Keywords: Localized; Muscle-invasive; Non-muscle-invasive; Bladder cancer; Checkpoint inhibitor; PD-1; PD-L1; CTLA-4; Treatment; Therapy;
Keywords: Immune checkpoint inhibitors; Biomarkers; Clinical studies; Immunotherapy; Hematologic malignancies; CTLA-4; PD-1;
Keywords: FDA; US Food and Drug Administration; BCG; Calmette and Guerin; DC; dendritic cell; APCs; antigen-presenting cells; TSAs; tumor specific antigens; TRA; tumor rejection antigen; gp96; glycoprotein of 96â¯kDa; CTLs; cytotoxic T cells; SEREX; serological an
Keywords: Cervical cancer; Immune check-point; Immunotherapy; CTLA-4; PD-1; Ipilimumab; Pembrolizumab; Nivolumab;
Keywords: AdV; adenovirus; ATP; adenosine triphosphate; APC; antigen presenting cell; CTLA-4; cytotoxic T lymphocyte antigen 4; CTL; cytotoxic T lymphocyte; CXCL/CCL; C-X-C motif ligands; DAMPs; damage-associated molecular pattern molecules; DC; dendritic cell; GIT
Keywords: ADAM; a disintegrin and metalloproteinase; APP; amyloid precursor protein; APC; antigen presenting cell; Aβ; β-amyloid; B7-H1; B7-homolog 1; CARD; caspase activation and recruitment domain; CCR; C-C chemokine receptor; CIM; C-protein induced myositis; C
Keywords: HPV; human papilloma virus; CC; cervical cancer; EC; endometrial cancer; CIN; cervical intraepithelial neoplasia; VIN; vulvar intraepithelial neoplasia; VaIN; vaginal intraepithelial neoplasia; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; PD-1; pr
Keywords: urinary bladder neoplasms; carcinoma; programmed cell death 1 receptor; immunotherapy; APC; antigen-presenting cell; BCG; bacillus Calmette-Guérin; CD; cluster of differentiation; CR; complete response; CTLA-4; cytotoxic T-lymphocyte-associated antigen-4
Keywords: APC; Antigen presenting cells; CIMP; CpG island methylator phenotype; CIN; chromosomal instability; CRC; colorectal cancer; CTLA-4; cytotoxic T lymphocyte-associated protein 4; DAMPs; danger-associated molecular patterns; FDA; US Food and Drug Administr
Keywords: ARID; Age Related Immune Differences; CD40L; CD40 ligand; CTLA-4; cytotoxic T lymphocyte antigen-4; IL; interleukin; Lag3; lymphocyte activation gene 3; MDSC; myeloid derived suppressor cell; MHC; major histocompatibility complex; mTOR; mammalian target o
Keywords: 5-FU; 5-fluoro-uracil; AAV; adeno-associated virus; ADAM; ADAM metallopeptidase domain; ADCC; antibody-dependent cell-mediated cytotoxicity; CCL; chemokine (C-C motif) ligand; CD; cluster of differentiation; CTLA-4; cytotoxic T-lymphocyte-associated ant
Keywords: 5FU; 5-fluorouracil; 95%CI; 95% confidence interval; AA; amino acid; AFP; alpha fetoprotein; AML; actue myeloid leukemia; Ang2; angiopoietin 2; ATP; adenosine triphosphate; BCLC; Barcelona-Clinic Liver Cancer classification; BSC; best supportive care; CAP
Keywords: CIITA; CTLA-4; De novo donor-specific antibodies; Chronic antibody-mediated rejection; Kidney transplantation;
Keywords: ICI; immune checkpoint inhibition; irAE; immune related adverse event; TME; tumor microenvironment; Melanoma; Biomarker; Checkpoint inhibitor; PD-1; CTLA-4;
Keywords: BATF; basic leucine zipper transcription factor; BM; bone marrow; Bregs; regulatory B cells; BTLA; B and T lymphocyte attenuator; CFSE; carboxyfluorescein succinimidyl ester; CML; cell mediated lympholysis; CNI; calcineurin inhibitor; CPM; counts per minu
Keywords: ARID; Age Related Immune Dysfunction; BCG; Bacille Calmette-Guérin; CAR; chimeric antigen receptor; CDMRP; Congressionally Directed Medical Research Program; CD40L; CD40 ligand; CpG; poly-(cysteine 5â² to guanine); CRISPR; clustered regularly interspace
Keywords: CTLA-4; cytotoxic T-lymphocyte-associated protein 4; ICI; immune checkpoint inhibitor; irAE; immune-related adverse event; mRSS; modified Rodnan skin score; PD-1; programmed cell death 1; PD-L1; programmed cell death ligand 1; RNAP3; RNA polymerase III;
Keywords: bsAb; bispecific antibody; CAR; chimeric antigen receptor; CDN; cyclic dinucleotides; CTL; cytotoxic T lymphocyte; CTLA-4; cytotoxic T-lymphocyte-associated protein 4; GM-CSF; granulocyte-monocyte colony stimulating factor; IR; irradiation; PD-1; Programm
Keywords: CAF; cancer associated fibroblast; GRP78; glucose-regulated protein 78; DC; dendritic cell; NK; natural killer cell; MDSC; myeloid-derived suppressor cell; TIL; tumor-infiltration lymphocyte; TAM; tumor-associated macrophage; NSCLC; non-small cell lung ca
Keywords: EGFR; Epidermal growth factor receptor; TP53; Tumor protein p53; KRAS; Kirsten rat carcoma viral oncogene; ALK; Anaplastic lymphoma kinase; RTK; Protein receptor tyrosine kinase; TKI; Tyrosine kinase inhibitor; PI3K; Phosphatidylinositol 3-kinase; NSCLC;
Keywords: DCs; dendritic cells; TPY; trypticase-phytone-yeast extract; MRS; de Man, Rogosa and Sharpe medium; GM-CSF; granulocytemacrophage colony-stimulating factor; SCFAs; short-chain fatty acids; LAB; lactic acid bacteria; CTLA-4; cytotoxic T-lymphocyte antigen
Keywords: CTLA-4; Immunotherapy; PD-1; PD-L1; Small-cell lung cancer;
Keywords: immune therapy; metastatic melanoma; targeted therapy; APC; antigen presenting cells; BRAF; v-RAF murine sarcoma viral oncogene; CRR; complete response rate; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; irAEs; immune related adverse events; KA;
Keywords: TME; tumour microenvironment; PD-1; programmed cell death 1; PD-L1; programmed death ligand 1; PD-L2; programmed death ligand 2; PTMs; post-translational histone modifications; DNMTi; DNA methyltransferase inhibitor; HDACi; histone deacetylase inhibitor;
Keywords: Immunology; primary immunodeficiency; whole-exome sequencing; hematopoietic stem cell transplantation; common variable immunodeficiency; severe combined immunodeficiency; hyper-IgE syndrome; AIP1; Actin-interacting protein 1; APDS; Activated PI3Kδ syndro
Keywords: BCG vaccine; cancer vaccines; cell cycle checkpoints; immunotherapy; urologic neoplasms; AE; adverse event; APC; antigen presenting cell; BCG; bacillus Calmette-Guérin; CAR; chimeric antigen receptor; CIS; carcinoma in situ; CTA; cancer testis antigen; C
Keywords: Biomarkers; Checkpoint molecules; Cytokines; Glioblastoma; Immunotherapy; Microbiome; Mutational landscape; CB; Cintredekin besudotox; CNS; Central nervous system; CTLA-4; Cytotoxic T lymphocyte antigen 4; CyTOF; Cytometry by time-of-flight; EGFR; Epiderm
Keywords: ETC; electron transport complexes; ROS/RNS; reactive oxygen or nitrogen spices; âÏm; mitochondrial inner membrane potential; TCA; TriCarboxylic acid cycle; MPTP; mitochondrial permeability transition pore; mtDNA; mitochondrial DNA; ND5; NADH dehydrogen
Keywords: single miscarriage; recurrent miscarriage; genetic alterations; chromosome abnormalities; genetic polymorphisms; karyotype; ACE; Angiotensin I converting enzyme; Bcl-2; B-cell lymphoma 2; CGH; comparative genomic hybridization; CYP; cytochrome P450; CTLA-
Keywords: Melanoma; PD-1; CTLA-4; Organ transplantation; Kidney failure;
Keywords: Urothelial carcinoma; Bladder cancer; Immunotherapy; Immune checkpoint blockade; PD-1; CTLA-4; Oncolytic virus;
Keywords: TME; tumour microenvironment; MSC; mesenchymal stem cell; NK; natural killer; APC; antigen presenting cell; EC; endothelial cell; ECM; extracellular matrix; CAF; cancer-associated fibroblast; EMT; epithelial-mesenchymal transition; αSMA; alpha smooth m
Keywords: Melanoma; Liquid biopsy; Circulating tumor cells; Cell-free circulating tumor DNA; Cell-free DNA; Cell-free microRNA; Ab; antibody; AIM1; absent in melanoma-1; AJCC; American Joint Committee on Cancer; BRAF; B-Raf proto-oncogene, serine/threonine kinase;
Keywords: Liver; Immunity; Tolerance; Autoimmunity; Antigen presentation; Innate lymphocytes; AIH; autoimmune hepatitis; ALD; autoimmune liver disease; APC; antigen-presenting cell; CTLA-4; cytotoxic T cell antigen-4; DC; dendritic cell; α-GC; α-galactosylceramid
Keywords: Hypophysitis; Autoimmune; CTLA-4; IgG4; Hypopituitarism; Diabetes insipidus;
Keywords: Cancer treatment; Radiotherapy; Checkpoint; Immunotherapy; CTLA-4; PD-L1;
Keywords: BRAF; v-raf murine sarcoma viral oncogene homolog; MEK; MAP kinase-ERK kinase; KIT; V-KIT Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; PD-1/PD-L1; programmed death-1/ programmed death-1 li
Keywords: RA; rheumatoid arthritis; DCs; dendritic cells; TolDCs; tolerogenic dendritic cells; NSAIDs; non-steroidal anti-inflammatory drugs; GC; glucocorticoids; DMARDs; disease-modifying anti-rheumatic drugs; TLRs; toll-like receptors; CLRs; cell surface C-type l
Keywords: HNSCC; Immunotherapy; CTLA-4; PD-1; Cetuximab; Vaccine; Chimeric antigen receptor;
Keywords: Gy; gray; Ab; antibody; TGF-β; transforming growth factor-β; TNF; tumor necrosis factor; SASP; senescence-associated secretory phenotype; MCP-1; monocyte chemoattractant protein-1; MHC; major histocompatibility complex; DAMP; damage-associated molecular
Keywords: Antibodies; Immunoconjugates; Immunotoxins; Ab; antibody; Ag; antigen; ADCC; antibody-dependent cell mediated cytotoxicity; ALL; acute lymphoblastic leukemia; AML; acute myeloid leukemia; AKT; protein kinase B; APC; antigen-presenting cell; Apo2L/TRAIL; t
Keywords: 17-AAG; 17-(Allylamino)-17-demethoxygeldanamycin; 17-DMAG; 17-Dimethylaminoethylamino-17-demethoxygeldanamycin; AKT; v-akt murine thymoma viral oncogene homolog; APC; antigen presenting cell; ATM; Ataxia telangiectasia mutated; ATR; Ataxia telangiectasia
Keywords: Radiation; Immunotherapy; Dose; Fractionation; MHC-I; major histocompatibility class I; ICAM-1; intercellular adhesion molecules-1; CEA; carcinoembryonic antigen; CTL; cytotoxic T cells; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; gp 100; glycopr
Keywords: Ag; antigen; APC; antigen presenting cell; AQP4; aquaporin 4; BDNF; brain-derived neurotrophic factor; CD; cluster of differentiation; CCL; C-C ligand; chABC; chondroitinase ABC; CNS; central nervous system; COX; cyclooxygenase; CTLA-4; cytotoxic T lymp
Keywords: 5-ALA; 5-aminolevulinic acid; 5-FU; 5-fluorouracil; APC; antigen presenting cell; BCC; basal cell carcinoma; CAP; cold atmospheric plasma; CM; cutaneous malignant melanoma; CNP; cerium oxide nanoparticle; CNT; carbon nanotube; COX-2; cyclooxygenase II; CP
Keywords: Breast cancer; Immune system; Biomarkers; Immunotherapies; Immune checkpoint blockade; Tumor vaccines; ADCC; antibody dependent cellular cytotoxicity; BiTES; bispecific single chain monoclonal antibodies; CAR; T cells engineered to express artificial chim
Keywords: AE; adverse effect; APC; antigen-presenting cells; CI; confidence interval; CP; carboplatin and paclitaxel; CR; complete response; CTLA-4; cytotoxic T-lymphocyte-associated antigen-4; cuSCC; cutaneous squamous cell carcinoma; FDA; Food and Drug Administ
Keywords: APC(s); antigen presentation cell(s); ARG1; arginase-1; Breg(s); regulatory B (cells); CAF(s); cancer-associated fibroblast(s); CD; cluster of differentiation protein; CD40L; cluster of differentiation protein 40 ligand; C/EBP; CAAT/enhancer binding prote